Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
| Autor: | Elisaf, Moses S., Bairaktari, Eleni Th, Nikolaides, C., Kakaidi, B., Tzallas, C. S., Katsaraki, A., Pavlidis, Nicholas |
|---|---|
| Přispěvatelé: | Pavlidis, Nicholas [0000-0002-2195-9961], Elisaf, Moses S. [0000-0003-0505-078X] |
| Jazyk: | angličtina |
| Rok vydání: | 2001 |
| Předmět: |
Cancer Research
Low density lipoprotein cholesterol Lipids/*blood Postmenopause/*blood Triazoles/*adverse effects chemistry.chemical_compound Risk Factors Drug activity Antineoplastic agents Apolipoprotein a1 Apolipoprotein e Aromatase Enzyme Inhibitors Middle aged High density lipoprotein cholesterol Apolipoprotein b Priority journal Cholesterol HDL/blood Lipoprotein blood level Apolipoprotein a-i medicine.diagnostic_test Letrozole Enzyme inhibitors Antineoplastic Agents/*adverse effects Middle Aged Lipid Lipids Postmenopause Triglycerides/blood Cholesterol Cholesterol blood level Apolipoproteins e Cholesterol LDL/blood Oncology Low-density lipoprotein Hormonal therapy Breast Neoplasms/blood/*drug therapy lipids (amino acids peptides and proteins) Female medicine.drug Human Apolipoproteins b Adult Apolipoproteins E/blood medicine.medical_specialty Hdl medicine.drug_class Apolipoprotein A-I/blood Clinical article Breast carcinoma Hypercholesterolemia Lipoprotein(a)/blood Antineoplastic Agents Breast Neoplasms Biology Triacylglycerol Article Ldl Apolipoproteins E Diet restriction Internal medicine Nitriles medicine Humans Triglycerides Apolipoproteins B Aged Aromatase inhibitor Apolipoprotein A-I Cholesterol HDL Cholesterol LDL Triazoles Lipid blood level Apolipoproteins B/blood Drug effect Tamoxifen Endocrinology chemistry Risk factors Enzyme Inhibitors/*adverse effects Nitriles/*adverse effects biology.protein Risk factor Breast neoplasms Lipid profile Controlled study Lipid parameters Lipoprotein Lipoprotein(a) |
| Zdroj: | European journal of cancer |
| Popis: | Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis. The drug can significantly reduce the levels of plasma oestrogens, which remain suppressed throughout the treatment. Data are scarce concerning the influence of these drugs on serum lipid levels. In the present study, we evaluated the effects of letrozole on the serum lipid profile in postmenopausal women with breast cancer. A total of 20 patients with breast cancer were treated with letrozole, 2.5 mg once daily. After an overnight fast, serum lipid parameters (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, apolipoproteins A1, B and E and lipoprotein (a)) were measured before treatment and at 8 and 16 weeks afterwards. A significant increase in total cholesterol (P = 0.05), LDL cholesterol (P < 0.01) and apolipoprotein B levels (P = 0.05) in the serum, as well as in the atherogenic risk ratios total cholesterol/HDL cholesterol (P < 0.005) and LDL cholesterol/HDL cholesterol (P < 0.005) was noticed after letrozole treatment. We conclude that letrozole administration in postmenopausal women with breast cancer has an unfavourable effect on the serum lipid profile. © 2001 Elsevier Science Ltd. All rights reserved. 37 12 1510 1513 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|